Journal article
Rivaroxaban Plus Aspirin in Patients With Vascular Disease and Renal Dysfunction From the COMPASS Trial
Abstract
BACKGROUND: Chronic kidney disease is associated with an increased risk of both bleeding and ischemic cardiovascular events.
OBJECTIVE: The purpose of this study was to determine the balance of risks and benefits from the dual pathway antithrombotic regimen (rivaroxaban 2.5 mg twice daily [bd] plus aspirin, compared with aspirin) in vascular patients with or without moderate renal dysfunction.
Authors
Fox KAA; Eikelboom JW; Shestakovska O; Connolly SJ; Metsarinne KP; Yusuf S
Journal
Journal of the American College of Cardiology, Vol. 73, No. 18, pp. 2243–2250
Publisher
Elsevier
Publication Date
5 2019
DOI
10.1016/j.jacc.2019.02.048
ISSN
0735-1097
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AgedAspirinCoronary Artery DiseaseCorrelation of DataDouble-Blind MethodDrug Therapy, CombinationFemaleFibrinolytic AgentsGlomerular Filtration RateHemorrhageHumansMaleMiddle AgedMyocardial InfarctionOutcome and Process Assessment, Health CarePeripheral Arterial DiseaseRenal Insufficiency, ChronicRisk AdjustmentRivaroxaban